Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the 17th agreement with a major pharmaceutical manufacturer, Regeneron, to lower prescription drug prices that Americans pay for some of the world’s most innovative drugs, in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price). The agreement will provide every State Medicaid program in the country access to MFN drug prices on new Regeneron products, resulting in hundreds of millions in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable Americans.The agreement ensures foreign nations can...